ASH Annual Meeting: Drugmakers Battle for Multiple Myeloma
In this video from Motley Fool Live, recorded on Dec. 7, Corinne Cardina, bureau chief of healthcare and cannabis, and Fool.com contributor Brian Orelli review data from the American Society of Hematology (ASH) annual meeting on multiple myeloma drugs targeting B-cell maturation antigen (BCMA). Companies are targeting BCMA with both chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies. Both types of treatment seek to bring T-cells in proximity to the cancer cells for the T-cells to kill them. It's a hot space that investors should keep an eye on as there's no clear winner yet.
Source Fool.com
